Biotek-snakken — Januar 2020
-
-
-
-
Jeg synes, at dette siger rigtig meget. Arimoclomol har modtaget betegnelser på fast track, forældreløst lægemiddel og pædiatrisk sygdom fra US Food and Drug Administration (FDA) og for nylig modtaget gennembrudsbetegnelse fra FDA.
Orphazyme evaluerer i øjeblikket, hvordan man kan tilbyde tidlig adgang i yderligere lande over tid, afhængig af drøftelser med lokale myndigheder og
fremskridt hen imod arkivering til lovgivningsmæssig godkendelse eller opnåelse af refusion.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind